CLINICAL
TRIALS |
Cholesterol
Lowering Agents to Slow Progression of Alzheimer's Disease (CLASP)
Assessing
Cognition: Interactive Voice Response Systems (IVR Study)
Vitamins
to Slow Alzheimer’s Disease (VITAL Study)
Valproate
In Dementia (The VALID Study) |
|
CHOLESTEROL
LOWERING AGENTS TO SLOW PROGRESSION OF ALZHEIMER'S DISEASE (CLASP)
Researchers have found that lowering cholesterol levels with
certain medications may have a positive impact on brain function and may
reduce the risk of Alzheimer’s disease. The CLASP Study is a national
clinical research study designed to examine the effectiveness of Simvastatin
(Zocor), a widely used cholesterol lowering medication, in slowing memory
decline in individuals with Alzheimer’s disease. The CLASP Study
is sponsored by the Alzheimer’s Disease Cooperative Study and funded
by the National Institute on Aging (NIA). Participants in this study will
be given either Simvastatin or placebo (inactive pill) for 21 months.
Throughout the study, participants will be assessed regularly by physicians
and other qualified health care professionals. Volunteers must be diagnosed
with mild to moderate Alzheimer's disease and have a study partner who
is familiar with the participant’s health to accompany the individual
to all eight clinic visits during the 21-month period. Stanford researchers
are currently seeking volunteers for the CLASP Study. For additional information
regarding this research study, please contact Alena Kleytman at (650)
849-0339 or by Email.
(Viewing PDF
requires Adobe
Acrobat Reader) |
ASSESSING
COGNITION: INTERACTIVE VOICE RESPONSE SYSTEMS (IVR Study)
The IVR Study assesses cognitive
changes using a touch-tone phone system. The convenience of answering
questions by dialing a toll-free number from one’s home phone may
make it easier for clinicians and researchers to detect small changes
in memory. We are currently seeking older adults age 65 and older to participate
in this research study. Participants will need a study partner, and both
will be asked to complete seven brief phone assessments and attend four
clinic visits over a 6-month period. Both study subjects and study partners
will be compensated up to a total of $250 for participation. For additional
information regarding this research study, please contact Shannon Hsu
at (650) 849-0222 or by Email.
|
VITAMINS
TO SLOW ALZHEIMER'S DISEASE (VITAL Study)
The VITAL Study is a nationwide
clinical research study to evaluate whether large daily doses of the nutritional
supplements folate, vitamins B6 and B12 will slow the rate of cognitive
decline in individuals with Alzheimer’s disease. VITAL is sponsored
by the Alzheimer’s Disease Cooperative Study and funded by the National
Institute on Aging (NIA). Participants in this study will be given either
daily high doses of folate, vitamin B6 and B12 or placebo (inactive pill)
for 18 months to determine whether these supplements are beneficial to
individuals with AD. Throughout the study, participants will be assessed
regularly by physicians and other qualified health care professionals.
The VITAL study has begun recruiting subjects at Stanford. For additional
information regarding this research study or to inquire about participating,
please contact Alena Kleytman at (650) 849-0339 or by Email.
|
VALPROATE
IN DEMENTIA (The VALID Study)
Valproate is an FDA approved
anticonvulsant medication which may be helpful in slowing cognitive decline
in Alzheimer’s disease and other related symptoms. The VALID Study
is a nationwide clinical research study to evaluate whether Valproate
is effective in delaying, weakening or preventing difficult behaviors
in individuals with Alzheimer’s disease. Researchers will also examine
whether Valproate has an effect on slowing the progression of Alzheimer’s
disease overall. VALID is sponsored by the Alzheimer’s Disease Cooperative
Study and funded by the National Institute on Aging (NIA). Participants
in this study will be assigned at random to receive Valproate or placebo
(inactive pill) for 26 months. Throughout the study, participants will
be assessed regularly by physicians and other qualified health care professionals.
This study has begun recruiting subjects. For additional information regarding
this research study or to inquire about participating, please contact
Alena Kleytman at (650) 849-0339 or by Email.
|
| previous
page |
